Legend Biotech Corporation American Depositary Shares (LEGN)
Company News
Legend Biotech reported strong Q1 2025 results, with CARVYKTI® net trade sales of $369 million and over 6,000 patients treated to date. The company received positive regulatory updates, expanded manufacturing capacity, and maintained a strong cash position of $1 billion, which is expected to provide financial runway into Q2 2026.
Shares of cell therapy company Legend Biotech Corp (NASDAQ:LEGN) were trading lower on Monday, after being among the top pharma gainers in the first week of June. The company's Carvykti drug is likely to return to growth and revive investor enthusiasm, according to Truist Securities. The Legend Biotech Analyst: Asthika Goonewardene initiated coverage of Legend Biotech with a Buy rating and price target of $88. The Legend Biotech Thesis: In a landmark collaboration with Johnson & Johnson (NYSE:JNJ), the company launched Carvykti, which is "the most attractive product" for treating multiple ...Full story available on Benzinga.com
Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Bristol Myers Squibb’s cell therapy Breyanzi won FDA approval Thursday for treatment of a common type of leukemia.
Bristol-Myers Squibb is a well-known blue-chip stock with a dividend yield exceeding 4.6%. Read why I'm rating BMY stock a Buy at this point.